Literature DB >> 29251034

Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.

Masato Ishida1, Yuki Kuroiwa1, Emiko Yoshida1, Masayo Sato1, Dominika Krupa2, Nathaniel Henry2, Kei Ikeda3, Yuko Kaneko4.   

Abstract

OBJECTIVES: To identify, describe and summarize evidence on residual symptoms and disease burdens in rheumatoid arthritis (RA) patients qualified as being in remission or low disease activity (LDA).
METHODS: A systematic literature review (SLR) was conducted according to Cochrane collaboration guidelines. The population of interest was adult patients with RA in remission or LDA. The reported outcomes of interest were any symptoms or burdens.
RESULTS: Fifty-one publications were identified through an eDatabase search. Together with 17 articles found through other sources, 68 were included for full text review. The most commonly reported residual symptoms were pain (number of studies = 25), fatigue (n = 21) and morning stiffness (n = 5). Reported disease burdens included mental health (n = 15), sleep disturbances (n = 7) and work productivity (n = 5), impairment in quality of life (n = 21), and functional disability (n = 34). Substantial residual symptoms and disease burdens were found to be present in patients in remission or LDA.
CONCLUSION: This is the first SLR to investigate residual symptoms and disease burdens in RA patients in remission or LDA. The results indicate that despite achieving conventional clinical targets, the disease continues to affect patients, suggesting the existence of unmet need under the current treatment paradigm.

Entities:  

Keywords:  Low disease activity; remission; residual symptom; rheumatoid arthritis; systematic literature review

Mesh:

Substances:

Year:  2018        PMID: 29251034     DOI: 10.1080/14397595.2017.1416940

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  12 in total

1.  Cannabis for rheumatic pain: hope or hype?

Authors:  Glen S Hazlewood; Omid Zahedi Niaki; Mary-Ann Fitzcharles
Journal:  Clin Rheumatol       Date:  2019-07-05       Impact factor: 2.980

2.  Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis.

Authors:  Andrew C Heisler; Jing Song; Dorothy D Dunlop; Alyssa Wohlfahrt; Clifton O Bingham; Marcy B Bolster; Daniel J Clauw; Wendy Marder; Kristine Phillips; Tuhina Neogi; Yvonne C Lee
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-07-21       Impact factor: 4.794

3.  Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Authors:  Fabio Massimo Perrotta; Antonia De Socio; Silvia Scriffignano; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

4.  Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain.

Authors:  Déborah Puyraimond-Zemmour; Benjamin Granger; Anna Molto; Cécile Gaujoux-Viala; Francis Guillemin; Adeline Ruyssen-Witrand; Maxime Dougados; Bruno Fautrel; Laure Gossec
Journal:  Arthritis Res Ther       Date:  2019-02-19       Impact factor: 5.156

Review 5.  Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases.

Authors:  Tal Gonen; Howard Amital
Journal:  Rambam Maimonides Med J       Date:  2020-01-30

6.  Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction.

Authors:  Yomei Shaw; Delphine S Courvoisier; Almut Scherer; Adrian Ciurea; Thomas Lehmann; Veronika K Jaeger; Ulrich A Walker; Axel Finckh
Journal:  RMD Open       Date:  2021-04

Review 7.  Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review.

Authors:  Andrew J Ostor; Ruta Sawant; Cynthia Z Qi; Aozhou Wu; Orsolya Nagy; Keith A Betts
Journal:  Adv Ther       Date:  2021-11-17       Impact factor: 3.845

8.  Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.

Authors:  Peter C Taylor; Rieke Alten; Jose María Álvaro Gracia; Yuko Kaneko; Chad Walls; Amanda Quebe; Bochao Jia; Natalia Bello; Jorge Ross Terres; Roy Fleischmann
Journal:  RMD Open       Date:  2022-03

9.  Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.

Authors:  Bruno Fautrel; Bruce Kirkham; Janet E Pope; Tsutomu Takeuchi; Carol Gaich; Amanda Quebe; Baojin Zhu; Inmaculada de la Torre; Francesco De Leonardis; Peter C Taylor
Journal:  J Clin Med       Date:  2019-09-05       Impact factor: 4.241

10.  Multimorbidity and Fatigue in Rheumatoid Arthritis: A Cross-Sectional Study of a Population-Based Cohort.

Authors:  John M Davis; Elena Myasoedova; Tina M Gunderson; Cynthia S Crowson
Journal:  Rheumatol Ther       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.